I think Matthias has hit it on the head. The trial results should be the next announcement of significance along with milestone payments from Merck. In light of several drug development programs plus a commercial partnership, this stock is looking way to cheap, IMO. I'm keeping my eyes forward and looking forward to clinical trial results.
